Paroxysmal Nocturnal Hemoglobinuria, High Sensitivity, WBC
Ordering Recommendation
Use to quantify or monitor paroxysmal nocturnal hemoglobinuria clone size. Preferred initial diagnostic test is Paroxysmal Nocturnal Hemoglobinuria (PNH), RBC and WBC (2005006).
Quantitative Flow Cytometry
1-4 days  
New York DOH Approval Status
Specimens from New York clients will be sent out to a New York DOH approved laboratory, if possible.
Submit With Order
Specimen Required
Patient Preparation
New York State Clients: Testing is only approved for the Paroxysmal Nocturnal Hemoglobinuria Panel (ARUP test code 2005006) on whole blood specimens.   
Lavender (EDTA), pink (K2EDTA), or green (sodium or lithium heparin).  
Specimen Preparation
Transport 4 mL whole blood. (Min: 4 mL)  
Storage/Transport Temperature
Unacceptable Conditions
Bone marrow. Clotted or hemolyzed specimens.  
Specimens must be analyzed within stability times provided.  
Ambient: 24 hours; Refrigerated: 72 hours; Frozen: Unacceptable  
Reference Interval
By report  
Interpretive Data
This test was developed according to published guidelines (Cytometry B Clin. Cytom. 2010; 78:211) and as updated in 2014 (Cytometry B Clin. Cytom. 2014; 86:44). WBC analysis is the most accurate measurement of the PNH clone size and uses FLAER and CD157 as GPI-linked markers with CD15 (PMNs) and CD64 (monocytes) as lineage-specific markers. The lower limits of detection are 0.005 percent for PMNs and 0.020 percent for monocytes.

For initial diagnosis of PNH, order High Sensitivity RBC and WBC Panel (ARUP test code 2005006). The presence of a subclinical PNH population in myelodysplastic bone marrow disorders, such as aplastic anemia or refractory anemia, may correlate with a positive immunotherapeutic response (Blood 2006; 107, 1308-1314).

For delineation of RBC Types II and III populations when the RBC clone size is greater than 1.000 percent, order PNH, High Sensitivity, RBC (ARUP test code 2004366).

Compliance Statement A: Analyte specific reagents (ASR) are used in many laboratory tests necessary for standard medical care and generally do not require U.S. Food and Drug Administration (FDA) approval or clearance. This test was developed and its performance characteristics determined by ARUP Laboratories. The U.S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions. This test should not be regarded as investigational or for research use.
CPT Code(s)
86356 x5
Component Test Code*Component Chart NameLOINC
2005004% PNH Monocytes60554-3
2005005% PNH PMN53831-4
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
  • (CD15, CD64, CD157, FLAER)
  • Eculizumab treatment monitoring assay